Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory AML; previously untreated AML not suitable for intensive Induction.

HR 41

A Phase 1/2, Open label, Mulitcenter 2 part study to access the safety, tolerability, Pharmaconetics, and efficacy, of AZD2811 Nanoparticle as Monotherapy or in combination in treatment – naïve or relapsed/refractory Acute Myeloid Leukemia.

Criteria to qualify for study: Drug used in study:
  • FLT3-ITD mutation-positive AML; first line therapy with standard induction chemotherapy

AML 48

A phase II study assessing CPX-351 (VYXEOS®) with Quizartinib for the treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML.

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AML, including MDS-transformed or treatment related.

AML 51

A phase 1 multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with newly diagnosed primary of secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD).

Criteria to qualify for study: Drug used in study:
  • High risk AML or MDS; ECOG 0 or 1

BMT 30

Graft-Versus-Tumor Augmentation with Nivolumab for High-Risk patients with MDS and AML after Allogeneic Stem Cell Transplantation using post-transplant Cyclophosphamide.